Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)
Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: Mar 10, 2026
Geographic Scope: United States
Clinical Area: Transthyretin Cardiac Amyloidosis
Application Due Date: May 5, 2026
Specific Area of Interest: This RFP seeks to support medical societies or professional organizations, in partnership with patient advocacy organizations, to develop, validate, and/or evaluate a shared decision-making tool (Decision Aid) aimed at improving decision quality, health outcomes, patient experience, and quality of care among individuals living with ATTR-CM.
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.